| Market Capitalization (Millions $) |
654 |
| Shares
Outstanding (Millions) |
48 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
14 |
| Net Income (TTM) (Millions $) |
-69 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Trius Therapeutics Inc was a biopharmaceutical company focused on the discovery, development, and commercialization of antibiotics for serious and life-threatening infections. It was founded in 2004 and was headquartered in San Diego, California.
The company's main focus was on developing next-generation antibiotics to combat drug-resistant bacterial infections. Their lead product, tedizolid phosphate (brand name Sivextro), received FDA approval in 2014 for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Trius Therapeutics was acquired by Cubist Pharmaceuticals in 2013 for approximately $818 million. Cubist Pharmaceuticals, in turn, was acquired by Merck & Co. in 2015.
Overall, Trius Therapeutics aimed to address the growing problem of antibiotic resistance by developing innovative antibiotics to effectively treat various infections.
|
